--- title: "TherapeuticsMD (TXMD) news: lawsuit" url: "https://aibio.space/companies/therapeuticsmd/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TXMD lawsuit news: TherapeuticsMD's Mayne Pharma suit is stayed; IMVEXXY patent cases against Teva and Sun continue. TherapeuticsMD, Inc." --- TXMD TherapeuticsMD, Inc. NASDAQ · United States # TherapeuticsMD (TXMD) news TXMD lawsuit news Legal · 2026-08-11 ## [TherapeuticsMD's Mayne Pharma suit is stayed; IMVEXXY patent cases against Teva and Sun continue](https://aibio.space/news/therapeuticsmds-mayne-pharma-suit-stayed-imvexxy-patent-cases-against/) TherapeuticsMD (Nasdaq: TXMD) sued Mayne Pharma LLC in Delaware over net working capital allowances and faces a countersuit. Teva and Sun Pharma are defendants in New Jersey patent cases over generic IMVEXXY. ## Latest TherapeuticsMD news 1. 2026-05-12 Company Updates [TherapeuticsMD reports first quarter 2026 results and strategic review](https://aibio.space/news/therapeuticsmd-reports-first-quarter-2026-results-strategic-review/) The royalty company reported net income from continuing operations of $103 thousand and cash of $8.4 million as of March 31, 2026, and said it still evaluates strategic alternatives. 2. 2026-04-01 Distress [TherapeuticsMD files late notice after printer error left out auditor report](https://aibio.space/news/therapeuticsmd-files-late-notice-after-printer-error-left-out-auditor/) TherapeuticsMD filed a Form 12b-25 notice on April 1, 2026 after a printer error left the predecessor auditor's report out of its 2025 annual report. The company reported a 2025 net loss of $569,000 and year-end cash of $7.5 million. 3. 2025-12-16 Listings [TherapeuticsMD holders approve raising authorized common stock to 640,000,000 shares](https://aibio.space/news/therapeuticsmd-holders-approve-raising-authorized-common-stock-640-000/) TherapeuticsMD stockholders approved raising authorized common stock to 640,000,000 shares at the December 15, 2025 annual meeting. The company had 11,574,362 shares outstanding at the record date, and the increase drew 548,884 votes against. ## TherapeuticsMD at a glance - **Ticker**: TXMD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.2 million ### Related companies - [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) NASDAQ: CGEM - [Insmed](https://aibio.space/companies/insmed/) NASDAQ: INSM - [Lyra Therapeutics](https://aibio.space/companies/lyra-therapeutics/) OTC: LYRA - [Compass Therapeutics](https://aibio.space/companies/compass-therapeutics/) NASDAQ: CMPX - [Viskase Holdings](https://aibio.space/companies/viskase/) OTC: VISK - [Korro Bio](https://aibio.space/companies/korro-bio/) NASDAQ: KRRO - [Immuneering](https://aibio.space/companies/immuneering/) NASDAQ: IMRX - [ITonis](https://aibio.space/companies/itonis/) OTC: ITNS ### Also on NASDAQ - [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) ADPT - [Alkermes](https://aibio.space/companies/alkermes/) ALKS - [Connect Biopharma Holdings](https://aibio.space/companies/connect-biopharma/) CNTB - [SL Science Holding](https://aibio.space/companies/sl-science/) SLBT - [PMGC Holdings](https://aibio.space/companies/pmgc/) ELAB - [Spruce Biosciences](https://aibio.space/companies/spruce-biosciences/) SPRB ## What TherapeuticsMD does TherapeuticsMD, Inc. is a pharmaceutical royalty company that owns or has rights to trademarks such as TherapeuticsMD, vitaMedMD, BocaGreenMD, BIJUVA and IMVEXXY. It was previously a women's healthcare company, and in December 2022 it changed its business to become a royalty company, receiving royalties on products licensed to pharmaceutical organizations with commercial capabilities. Under the Mayne Transaction, which closed on December 30, 2022, Mayne Pharma LLC received an exclusive license to commercialize IMVEXXY, BIJUVA and prescription prenatal vitamins sold under the BocaGreenMD and vitaMedMD brands in the United States. TherapeuticsMD also assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. Mayne Pharma agreed to pay royalties on U.S. net sales of the products, starting at 8.0% on the first $80.0 million in annual net sales, for 20 years after the closing date. It also agreed to pay minimum annual royalties of $3.0 million per year for 12 years, subject to adjustment. | Product or program | What it is | Stage | |---|---|---| | IMVEXXY | Licensed to Mayne Pharma for U.S. commercialization | Licensed to Mayne Pharma (United States) | | BIJUVA | Licensed to Mayne Pharma for U.S. commercialization | Licensed to Mayne Pharma (United States) | | ANNOVERA | Exclusive license assigned to Mayne Pharma for U.S. commercialization | Assigned to Mayne Pharma (United States) | Summarised from the company's [10-K/A filed Apr 1, 2026](https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/ea0275992-10ka1_therap.htm). ## TherapeuticsMD annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$1.8 million](https://www.sec.gov/Archives/edgar/data/25743/000101376225003442/) | | Net income (loss) | [-$569,000](https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/) | [-$2.2 million](https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/) | | Cash and equivalents | [$7.5 million](https://www.sec.gov/Archives/edgar/data/25743/000121390026087768/) | [$5.1 million](https://www.sec.gov/Archives/edgar/data/25743/000121390025042697/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about TherapeuticsMD Is TherapeuticsMD involved in a lawsuit? Our latest story on this, dated Aug 11, 2026: "TherapeuticsMD's Mayne Pharma suit is stayed; IMVEXXY patent cases against Teva and Sun continue". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/therapeuticsmds-mayne-pharma-suit-stayed-imvexxy-patent-cases-against/). What is the ticker symbol of TherapeuticsMD? TherapeuticsMD, Inc. trades under the ticker TXMD on NASDAQ. Where is TherapeuticsMD listed? TherapeuticsMD, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:29TA. What is the SEC CIK of TherapeuticsMD? The SEC Central Index Key (CIK) for TherapeuticsMD, Inc. is 25743. Its filings are on SEC EDGAR. How many shares does TherapeuticsMD have outstanding? 11,574,362 shares as of 2026-08-09, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is TherapeuticsMD listed under? Our directory records TherapeuticsMD, Inc. under United States. What does TherapeuticsMD do? Our directory classifies TherapeuticsMD, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of TherapeuticsMD? The ISIN recorded for TherapeuticsMD, Inc. is US88338N2062. Does aibio.space cover TherapeuticsMD? aibio.space lists TherapeuticsMD, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is TherapeuticsMD incorporated? SEC records list its state or country of incorporation as NV. What does TherapeuticsMD develop? TherapeuticsMD, Inc. is a pharmaceutical royalty company that owns or has rights to trademarks such as TherapeuticsMD, vitaMedMD, BocaGreenMD, BIJUVA and IMVEXXY. It was previously a women's healthcare company, and in December 2022 it changed its business to become a royalty company, receiving royalties on products licensed to pharmaceutical organizations with commercial capabilities. What is IMVEXXY from TherapeuticsMD? IMVEXXY: Licensed to Mayne Pharma for U.S. commercialization Stage: Licensed to Mayne Pharma (United States). What is BIJUVA from TherapeuticsMD? BIJUVA: Licensed to Mayne Pharma for U.S. commercialization Stage: Licensed to Mayne Pharma (United States). Is TherapeuticsMD profitable? TherapeuticsMD, Inc. reported a net loss of $569,000 for the fiscal year ended Dec 31, 2025, per its annual report to the SEC. How much cash does TherapeuticsMD have? $9.2 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: TherapeuticsMD Members talk about TherapeuticsMD (TXMD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at TherapeuticsMD, newest first. Each line links the filing it comes from. 1. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/25743/000121390026037914/ea0284509-nt10k_therap.htm) 2. 2026-01-21 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/25743/000121390026005779/ea0273436-8k_therapeu.htm) 3. 2025-12-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/25743/000121390025122240/ea0269797-8k_therap.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TXMD on TradingView](https://www.tradingview.com/symbols/NASDAQ-TXMD/). ## SEC filings and registration - **SEC name**: TherapeuticsMD, Inc. - **CIK**: 25743 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TXMD (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431 - **Phone**: 561-961-1900 - **Shares outstanding**: 11,574,362 as of 2026-08-09 (10-Q filed 2026-08-11) - **Former names**: AMHN, Inc.; CROFF ENTERPRISES INC; CROFF OIL CO ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/25743/000121390026087768/ea0297949-10q_therapeutics.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/25743/000121390026087756/ea0298979-8k_therapeu.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/25743/000121390026055081/ea0286988-10q_therapeutics.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/25743/000121390026055070/ea0289776-8k_therapeu.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/ea0283239-8k_therapeu.htm) filed 2026-03-30 - [10-K](https://www.sec.gov/Archives/edgar/data/25743/000121390026036515/ea0275992-10k_therape.htm) filed 2026-03-30 - [8-K](https://www.sec.gov/Archives/edgar/data/25743/000121390026005779/ea0273436-8k_therapeu.htm) filed 2026-01-21 - [8-K](https://www.sec.gov/Archives/edgar/data/25743/000121390025122240/ea0269797-8k_therap.htm) filed 2025-12-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000025743), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details TherapeuticsMD, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TXMD, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: TherapeuticsMD, Inc. - **Ticker**: TXMD - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US88338N2062 - **Other listed symbols**: GETTEX:29TA - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TXMD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/therapeuticsmd/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "TherapeuticsMD (TXMD) news: lawsuit", 2026-10-31, https://aibio.space/companies/therapeuticsmd/